283 related articles for article (PubMed ID: 21167347)
1. Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial.
Gepner AD; Piper ME; Johnson HM; Fiore MC; Baker TB; Stein JH
Am Heart J; 2011 Jan; 161(1):145-51. PubMed ID: 21167347
[TBL] [Abstract][Full Text] [Related]
2. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial.
Johnson HM; Gossett LK; Piper ME; Aeschlimann SE; Korcarz CE; Baker TB; Fiore MC; Stein JH
J Am Coll Cardiol; 2010 May; 55(18):1988-95. PubMed ID: 20236788
[TBL] [Abstract][Full Text] [Related]
3. Smoking intensity and lipoprotein abnormalities in active smokers.
Gossett LK; Johnson HM; Piper ME; Fiore MC; Baker TB; Stein JH
J Clin Lipidol; 2009 Dec; 3(6):372-8. PubMed ID: 20161531
[TBL] [Abstract][Full Text] [Related]
4. Smoking habits and lipoproteins in British women.
Razay G; Heaton KW
QJM; 1995 Jul; 88(7):503-8. PubMed ID: 7633876
[TBL] [Abstract][Full Text] [Related]
5. Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution.
Freeman DJ; Griffin BA; Murray E; Lindsay GM; Gaffney D; Packard CJ; Shepherd J
Eur J Clin Invest; 1993 Oct; 23(10):630-40. PubMed ID: 8281981
[TBL] [Abstract][Full Text] [Related]
6. Relationships between Smoking Status, Cardiovascular Risk Factors, and Lipoproteins in a Large Japanese Population.
Nakamura M; Yamamoto Y; Imaoka W; Kuroshima T; Toragai R; Ito Y; Kanda E; J Schaefer E; Ai M
J Atheroscler Thromb; 2021 Sep; 28(9):942-953. PubMed ID: 33116031
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of smoking and smoking cessation on exercise stress testing: three-year outcomes from a randomized clinical trial.
Asthana A; Piper ME; McBride PE; Ward A; Fiore MC; Baker TB; Stein JH
Am Heart J; 2012 Jan; 163(1):81-87.e1. PubMed ID: 22172440
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled smoking cessation study: transient increase in plasma high density lipoprotein but no change in lipoprotein oxidation resistance.
Priemé H; Nyyssönen K; Grønbaek K; Klarlund M; Loft S; Tønnesen P; Salonen JT; Poulsen HE
Scand J Clin Lab Invest; 1998 Feb; 58(1):11-8. PubMed ID: 9516652
[TBL] [Abstract][Full Text] [Related]
9. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
Otvos JD; Guyton JR; Connelly MA; Akapame S; Bittner V; Kopecky SL; Lacy M; Marcovina SM; Muhlestein JB; Boden WE
J Clin Lipidol; 2018; 12(2):348-355.e2. PubMed ID: 29409728
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol changes in smoking cessation using the transdermal nicotine system. Transdermal Nicotine Study Group.
Allen SS; Hatsukami D; Gorsline J
Prev Med; 1994 Mar; 23(2):190-6. PubMed ID: 8047525
[TBL] [Abstract][Full Text] [Related]
11. Impact of cigarette smoking cessation on high-density lipoprotein functionality.
Takata K; Imaizumi S; Kawachi E; Suematsu Y; Shimizu T; Abe S; Matsuo Y; Tsukahara H; Noda K; Yahiro E; Zhang B; Uehara Y; Miura S; Saku K
Circ J; 2014; 78(12):2955-62. PubMed ID: 25319317
[TBL] [Abstract][Full Text] [Related]
12. Serum lipid, lipoprotein-cholesterol and apolipoproteins A-I and B of smoking and non-smoking males.
Sirisali K; Kanluan T; Poungvarin N; Prabhant C
J Med Assoc Thai; 1992 Dec; 75(12):709-13. PubMed ID: 1308540
[TBL] [Abstract][Full Text] [Related]
13. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial.
Hummel J; Westphal S; Weber-Hamann B; Gilles M; Lederbogen F; Angermeier T; Luley C; Deuschle M; Kopf D
J Clin Psychiatry; 2011 Jul; 72(7):885-91. PubMed ID: 21294998
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence.
Aday AW; Lawler PR; Cook NR; Ridker PM; Mora S; Pradhan AD
Circulation; 2018 Nov; 138(21):2330-2341. PubMed ID: 30021845
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein lipids in older people. Results from the Cardiovascular Health Study. The CHS Collaborative Research Group.
Ettinger WH; Wahl PW; Kuller LH; Bush TL; Tracy RP; Manolio TA; Borhani NO; Wong ND; O'Leary DH
Circulation; 1992 Sep; 86(3):858-69. PubMed ID: 1516198
[TBL] [Abstract][Full Text] [Related]
16. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
17. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Impact of Smoking and Smoking Cessation on Inflammatory Markers of Cardiovascular Disease Risk.
King CC; Piper ME; Gepner AD; Fiore MC; Baker TB; Stein JH
Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):374-379. PubMed ID: 27932354
[TBL] [Abstract][Full Text] [Related]
19. Effect of testosterone enanthate on serum lipoproteins in man.
Anderson RA; Wallace EM; Wu FC
Contraception; 1995 Aug; 52(2):115-9. PubMed ID: 8536448
[TBL] [Abstract][Full Text] [Related]
20. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
